Aimmune chief Stephen Dilly, M.B.B.S., Ph.D., is calling it a day.
A tax credit that allows biopharma companies to recoup some of the cost of developing drugs for rare diseases could be abolished if a Republican tax reform…
Following poor results from Roche and AstraZeneca, Sanofi says it is canning a phase 2 trial in idiopathic pulmonary fibrosis.
Five Prime Therapeutics has tapped into its existing management to replace current president and CEO Rusty Williams.
Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.
Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.
Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.
French biotech Biophytis has raised the funds it needs to start midstage trials of two drugs for age-related diseases via a private placement.
Rhythm Pharmaceuticals has topped its expectations in its IPO, selling more shares—at a higher price—than expected when it announced its intention to go public…
Intra-Cellular Therapies raised its target of $150 million, which will help it prepare for an FDA filing for lumateperone in schizophrenia next year.